IONS — Recent News Coverage
All news mentioning IONS in ESEN's AI-graded feed
News stories with IONS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on IONS. See /coverage/IONS for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-10-25
LOW
BULLISH
CORR0.42
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside (NASDAQ:IONS)
$IONS
◈ ESEN AI
IONS receives a bullish long-term thesis update centered on commercial execution and pipeline maturation. The analyst frames the investment case around product launches, royalty acceleration, and pipeline advancement of…
SEEKINGALPHA.COM
·
2026-07-29
NEUTRAL
NEUTRAL
CORR0.42
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
$IONS
◈ ESEN AI
IONS Q2 2026 earnings call represents a standard quarterly earnings disclosure with limited headline-moving catalyst potential. Earnings call transcripts are routine corporate communication events that typically move st…
SEEKINGALPHA.COM
·
2026-07-22
NEUTRAL
BULLISH
CORR0.42
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (NASDAQ:ARWR)
$ARWR
$IONS
◈ ESEN AI
Arrowhead Pharmaceuticals (ARWR) reported Phase 3 plozasiran data for severe hypertriglyceridemia (sHTG), a rare lipid disorder with limited treatment options. The clinical readout appears to have catalyzed investor opt…
SEEKINGALPHA.COM
·
2026-07-16
NEUTRAL
BULLISH
CORR0.42
Ionis Pharmaceuticals: The Heartbreak Is Priced In (NASDAQ:IONS)
$IONS
◈ ESEN AI
Ionis Pharmaceuticals (IONS) is receiving a Buy rating from analysts who argue that negative sentiment around reimbursement and competitive pressures has already been priced into the stock, creating a disconnect between…
MANILATIMES.NET
·
2026-07-14
HIGH
BULLISH
CORR0.72
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
$BIIB
$IONS
◈ ESEN AI
Biogen's diranersen Phase 2 CELIA trial results represent a potentially significant advancement in Alzheimer's disease treatment, with the compound demonstrating consistent clinical efficacy across multiple prespecified…
SEEKINGALPHA.COM
·
2026-07-09
HIGH
BEARISH
CORR0.42
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail - Why You Shouldn't Panic (AZN)
$AZN
$IONS
◈ ESEN AI
AstraZeneca (AZN) and Ionis Pharma (IONS) face significant near-term headwinds following the Wainua Phase 3 trial failure in heart disease treatment. This late-stage clinical setback eliminates a previously anticipated …
RTTNEWS.COM
·
2026-07-09
LOW
NEUTRAL
CORR0.15
Morning Market Movers: VRAX, AFJK, SDOT, IONS See Big Swings
$VRAX
$AFJK
$SDOT
$IONS
◈ ESEN AI
This premarket activity report identifies four small-cap equities experiencing elevated volatility during early trading hours on Thursday. The stocks—VRAX, AFJK, SDOT, and IONS—show noticeable price movements, though th…
FINANCE.YAHOO.COM
·
2026-07-08
NEUTRAL
BULLISH
CORR0.42
Is Ionis Pharmaceuticals, Inc. (IONS) Stock a Buy After Tryngolza’s FDA Approval?
$IONS
◈ ESEN AI
Ionis Pharmaceuticals (IONS) received incremental positive momentum following FDA approval of Tyngolza, a key pipeline asset. Analyst coverage reflected this milestone through a $5 price target increase by H.C. Wainwrig…
FINANCE.YAHOO.COM
·
2026-07-02
NEUTRAL
NEUTRAL
CORR0.45
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum
$IONS
◈ ESEN AI
Ionis Pharmaceuticals (IONS) has been selected by TimesSquare Capital Management's U.S. Mid Cap Growth Strategy, reflecting institutional conviction in the company's clinical momentum. This portfolio positioning suggest…
INSIDERMONKEY.COM
·
2026-07-02
NEUTRAL
BULLISH
CORR0.42
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals Inc. (IONS) on Clinical Momentum
$IONS
◈ ESEN AI
Ionis Pharmaceuticals (IONS) has been identified as a core holding within TimesSquare Capital Management's mid-cap growth strategy, with the selection predicated on clinical momentum and therapeutic pipeline progression…
SEEKINGALPHA.COM
·
2026-06-25
HIGH
BULLISH
CORR0.72
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction - Slideshow (NASDAQ:IONS) 2026-06-25
$IONS
◈ ESEN AI
IONS has secured FDA approval for TRYNGOLZA, a potentially market-shifting therapeutic targeting severe hypertriglyceridemia with acute pancreatitis risk reduction. This regulatory milestone represents a significant com…
SEEKINGALPHA.COM
·
2026-06-25
HIGH
BULLISH
CORR0.72
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
$IONS
◈ ESEN AI
IONS has secured FDA approval for TRYNGOLZA, marking a significant commercial milestone in the treatment of severe hypertriglyceridemia with acute pancreatitis risk reduction. This approval represents validation of the …
FINANCE.YAHOO.COM
·
2026-06-16
NEUTRAL
BULLISH
CORR0.42
Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?
$IONS
◈ ESEN AI
IONS has been highlighted among top genomics equities following a positive Phase 3 data readout for bepirovirsen, a partnership program with GSK. The 19% functional cure rate versus 0% for standard care represents a cli…
SEEKINGALPHA.COM
·
2026-06-15
LOW
NEUTRAL
CORR0.12
Ionis Pharmaceuticals, Inc. (IONS) Presents at National Lipid Association (NLA) 2026 Scientific Sessions - Slideshow (NASDAQ:IONS) 2026-06-15
$IONS
◈ ESEN AI
Ionis Pharmaceuticals (IONS) presented research findings at the National Lipid Association's 2026 Scientific Sessions, a routine disclosure event common among biopharmaceutical firms. Conference presentations represent …
SEEKINGALPHA.COM
·
2026-06-15
LOW
NEUTRAL
CORR0.15
Ionis Pharmaceuticals, Inc. (IONS) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow (NASDAQ:IONS) 2026-06-15
$IONS
◈ ESEN AI
IONS presented clinical or pipeline data at the Endocrine Society's Annual Meeting (ENDO 2026), a standard industry conference. Presentation at specialty medical conferences is routine corporate communication and does n…
EXPLORE OTHER FILTERS